Literature DB >> 28689653

WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013.

.   

Abstract

This article presents the World Health Organization's (WHO) recommendations on the use of fractional doses of yellow fever vaccines excerpted from the "Yellow fever vaccine: WHO position on the use of fractional doses - June 2017, Addendum to Vaccines and vaccination against yellow fever WHO: Position Paper - June 2013″, published in the Weekly Epidemiological Record [1,2]. This addendum to the 2013 position paper pertains specifically to use of fractional dose YF (fYF) vaccination (fractional dose yellow fever vaccination refers to administration of a reduced volume of vaccine dose, which has been reconstituted as usual per manufacturer recommendations) in the context of YF vaccine supply shortages beyond the capacity of the global stockpile. The current WHO position on the use of yellow fever (YF) vaccine is set out in the 2013 WHO position paper on vaccines and vaccination against YF and those recommendations are unchanged. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of Yellow Fever vaccines were discussed by SAGE in October 2016; evidence presented at these meetings can be accessed at: www.who.int/immunization/sage/meetings/2016/October/presentations_background_docs/en/.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28689653     DOI: 10.1016/j.vaccine.2017.06.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.

Authors:  Amanda Makha Bifani; Eugenia Z Ong; Ruklanthi de Alwis
Journal:  Curr Treat Options Infect Dis       Date:  2020-07-10

Review 2.  Fractional-dose yellow fever vaccination: an expert review.

Authors:  Anna H E Roukens; Leo G Visser
Journal:  J Travel Med       Date:  2019-09-02       Impact factor: 39.194

3.  Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.

Authors:  Derick Kimathi; Aitana Juan; Philip Bejon; Rebecca F Grais; George M Warimwe
Journal:  Wellcome Open Res       Date:  2019-11-20

4.  Yellow Fever Virus Down-Regulates mRNA Expression of SOCS1 in the Initial Phase of Infection in Human Cell Lines.

Authors:  Michael B Yakass; David Franco; Osbourne Quaye
Journal:  Viruses       Date:  2020-07-25       Impact factor: 5.048

5.  Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.

Authors:  Olubukola T Idoko; Cristina Domingo; Milagritos D Tapia; Samba O Sow; Christof Geldmacher; Elmar Saathoff; Beate Kampmann
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

6.  Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.

Authors:  Bettie W Kareko; Brian L Booty; Chad D Nix; Zoe L Lyski; Mark K Slifka; Ian J Amanna; William B Messer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 7.759

7.  Late or Lack of Vaccination Linked to Importation of Yellow Fever from Angola to China.

Authors:  Rui Song; Shengcan Guan; Shui Shan Lee; Zhihai Chen; Chen Chen; Lifen Han; Yanli Xu; Ang Li; Hui Zeng; Hanhui Ye; Fujie Zhang
Journal:  Emerg Infect Dis       Date:  2018-07-17       Impact factor: 6.883

Review 8.  Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Authors:  Kay M Tomashek; Mark Challberg; Seema U Nayak; Helen F Schiltz
Journal:  Vaccines (Basel)       Date:  2019-11-08

9.  Repurposing the yellow fever vaccine for intratumoral immunotherapy.

Authors:  Maria Angela Aznar; Carmen Molina; Alvaro Teijeira; Inmaculada Rodriguez; Arantza Azpilikueta; Saray Garasa; Alfonso R Sanchez-Paulete; Luna Cordeiro; Iñaki Etxeberria; Maite Alvarez; Sergio Rius-Rocabert; Estanislao Nistal-Villan; Pedro Berraondo; Ignacio Melero
Journal:  EMBO Mol Med       Date:  2019-11-19       Impact factor: 12.137

Review 10.  Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.

Authors:  Amanda Makha Bifani; Eugenia Z Ong; Ruklanthi de Alwis
Journal:  Curr Treat Options Infect Dis       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.